Frank Sciavolino
Principal investigator, leads Thetis Pharmaceuticals LLC.
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$9.0MFederal grants as PI12 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
12 awards · $9.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 6, 2021 | NIH | SBIR Phase II Development of a Novel Resolvin-Based Therapy for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) | $300K | Thetis Pharmaceuticals LLC |
| Apr 17, 2020 | NIH | SBIR Phase II Development of TP-252 for the Maintenance of Remission in Pediatric Ulcerative Colitis Patients | $498K | Thetis Pharmaceuticals LLC |
| Feb 20, 2020 | NIH | SBIR Phase II Development of TP-352 for the Treatment of Pediatric Non-alcoholic Steatohepatitis | $2.0M | Thetis Pharmaceuticals LLC |
| Aug 29, 2019 | NIH | SBIR Phase II Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients | $572K | Thetis Pharmaceuticals LLC |
| Aug 28, 2019 | NIH | SBIR Phase II Development of TP-352 for the Treatment of Pediatric Non-alcoholic Steatohepatitis | $296K | Thetis Pharmaceuticals LLC |
| Apr 30, 2019 | NIH | SBIR Phase II Development of TP-252 for the Maintenance of Remission in Pediatric Ulcerative Colitis Patients | $1.2M | Thetis Pharmaceuticals LLC |
| Jan 23, 2019 | NIH | SBIR Phase I Development of TP-317 for the Treatment of Eosinophilic Esophagitis | $294K | Thetis Pharmaceuticals LLC |
| Sep 20, 2018 | NIH | SBIR Phase II Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients | $2.0M | Thetis Pharmaceuticals LLC |
| Sep 14, 2018 | NIH | SBIR Phase II Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients | $1.4M | Thetis Pharmaceuticals LLC |
| May 4, 2018 | NIH | SBIR Phase II Development of TP-252 for the Maintenance of Remission in Pediatric Ulcerative Colitis Patients | $205K | Thetis Pharmaceuticals LLC |
| Jan 8, 2018 | NIH | SBIR Phase II Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients | $78K | Thetis Pharmaceuticals LLC |
| Sep 18, 2017 | NIH | SBIR Phase II Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients | $206K | Thetis Pharmaceuticals LLC |
Peer ranks
Federal funding#88
Awards as PI#86
Patents#273
Companies
- Thetis Pharmaceuticals LLCLeads (SEC Form D) · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.